Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial
Annals of the Rheumatic Diseases · 2025-12 · 84 (12) · 2103-2114
DOI: 10.1016/j.ard.2025.07.026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-12. Verfasst von Yves-Marie Pers und 36 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Regenerative Medicine and Biotherapy, Univ Montpellier, INSERM UMR 1183, Clinical Immunology and Osteoarticular Diseases Therapeutic Un…. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council.
Abstract (Originalsprache)
OBJECTIVES: This study aims to evaluate the efficacy of intra-articular autologous adipose-derived ex vivo expanded mesenchymal stromal cells (ADSC) on patient-reported outcome (pain and function) in symptomatic mild-to-moderate tibiofemoral knee osteoarthritis (OA). METHODS: Participants were randomised in a prospective, double-blind, controlled phase 2b study to receive 1 single intra-articular injection in 3 separate groups: ADSC low dose 2 × 106 cells; ADSC high dose 10 × 106 cells; or saline placebo. The primary outcome was the rate of OsteoArthritis Research Society International (OARSI)/Outcome MEasures in Rheumatology (OMERACT) 'strict responders' defined by improvements from baseline reported to 0 to 100 mm scale in Western Ontario and McMaster University Osteoarthritis index (WOMAC) pain or physical function subscores ≥50% with minimal absolute changes ≥20 mm at 6 months. Secondary outcomes included an evaluation of WOMAC pain, WOMAC function, quality of life (36-Item Short Form Health Survey), WOMAC and Knee injury and OA Outcome Score global change, magnetic resonance imaging cartilage thickness changes and safety from baseline to 12-month follow-up. RESULTS: One hundred thirty-five patients were randomised from September 2016 to March 2022 (mean age, 58.3 [SD, 6.5] years; 58 [43%] women), 99 (73%) received allocated intervention, and 97 were analysed. After 6 months, treatment with ADSC versus placebo injection, 26 patients (47.3%) versus 23 patients (54.8%) were strict OARSI/OMERACT responders (relative risk 0.86 [95% CI: 0.58-1.28]; P = .46). Individuals showed different patterns in cartilage thickness change between timepoints across tibiofemoral articular surfaces, but overall secondary outcomes showed no significant-group differences. CONCLUSIONS: Among patients with symptomatic mild-to-moderate knee OA, a single intra-articular injection of 2 × 106 or 10 × 106 autologous ADSC compared with injection of saline placebo did not significantly improve pain and function. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT02838069, https://clinicaltrials.gov/study/NCT02838069/EudraCT number: 2015-002125-19, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-002125-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute for Regenerative Medicine and Biotherapy, Univ Montpellier, INSERM UMR 1183, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier, Montpellier, France. Electronic address: ym-pers@…
- Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm,…
- EFS (Etablissement Français du Sang), Grenoble, St Ismier, and Toulouse Cedex 3, France.
- Department for Orthopedic and Trauma Surgery, Berlin, Germany.
- Institute for Regenerative Medicine and Biotherapy, Univ Montpellier, INSERM UMR 1183, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier, Montpellier, France.
- Rheumatology Department, Sorbonne University, INSERM CRSA, Hôpital Saint-Antoine, Paris, France.
Förderung
- European Research Council
Zitieren
APA
Pers, Y. M., Schrezenmeier, H., Fleury-Cappellesso, S., Nöth, U., Rackwitz, L., Ferreira, R., Berenbaum, F., Ruyssen-Witrand, A., Thurlings, R. M., Addimanda, O., Lisignoli, G., Ramonda, R., Shannon, F., Punzi, L., Baillet, A., McCaskie, A. W., McDonnell, S., O'Callaghan, J., Turmezei, T., …, & ADIPOA2 consortium (2025). Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Annals of the Rheumatic Diseases, 84(12), 2103-2114. https://doi.org/10.1016/j.ard.2025.07.026
Vancouver
Pers YM, Schrezenmeier H, Fleury-Cappellesso S, Nöth U, Rackwitz L, Ferreira R, et al. Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial. Annals of the Rheumatic Diseases. 2025;84(12):2103-2114. doi:10.1016/j.ard.2025.07.026
BibTeX
@article{Pers2025,
author = {Pers, Yves-Marie and Schrezenmeier, Hubert and Fleury-Cappellesso, Sandrine and Nöth, Ulrich and Rackwitz, Lars and Ferreira, Rosanna and Berenbaum, Francis and Ruyssen-Witrand, Adeline and Thurlings, Rogier Martijn and Addimanda, Olga and Lisignoli, Gina and Ramonda, Roberta and Shannon, Fintan and Punzi, Leonardo and Baillet, Athan and McCaskie, Andrew W and McDonnell, Stephen and O'Callaghan, Jenny and Turmezei, Tom and Kessler, Dimitri A and Lotfi, Ramin and Rojewski, Markus and Duffy, Aoife and Finnerty, Andrew and Moisan, Anaïck and Brochot-Dechet, Helene and Aubery-Rousselet, Mathilde and Michon, Amélie and Bouzas-Rodriguez, Jimena and Pullig, Oliver and Broussous, Sylvie and Nogue, Erika and Amico, Maïlis and Picot, Marie-Christine and Barry, Frank and Jorgensen, Christian and ADIPOA2 consortium, ADIPOA2 consortium},
title = {Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
number = {12},
pages = {2103--2114},
doi = {10.1016/j.ard.2025.07.026}
}
EUVIMED